P2, N=92, Completed, University of Nebraska | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Nov 2025

We employed an EGFR-TKI-naïve syngeneic Egfr-mutant mouse model and evaluated effects of anti-VEGF, anti-PD-L1, carboplatin, and paclitaxel as monotherapies and combinations, with TME analysis via immunohistochemistry (IHC), flow cytometry, and RNA sequencing. CD8+ T-cell depletion did not attenuate the effect of paclitaxel plus low-dose anti-VEGF, and IHC and RNA sequencing revealed increased natural killer cell infiltration, suggesting a CD8+ T-cell-independent, innate immune mechanism. These findings provide preclinical evidence that the evaluated anti-VEGF has limited immunomodulatory activity in EGFR-TKI-naïve Egfr-mutant tumors with a non-inflamed TME, and suggest immunotherapeutic strategies beyond CD8+ T-cell-mediated immunity warrant investigation.

P1, N=222, Recruiting, Shandong Boan Biotechnology Co., Ltd. | -> Recruiting | Phase classification: PN/A --> P1

Ultrasensitive ctDNA analyses demonstrated high baseline detection rates and near-universal clearance after abbreviated neoadjuvant therapy, supporting further investigation of ctDNA-guided de-escalation strategies in this setting. ClinicalTrials.gov Identifier: NCT03716180.

SF also enhanced the sensitivity of breast cancer cells to paclitaxel...Collectively, these findings reveal that SF exerts potent anti-metastatic effects by modulating tumor-bloodstream-immune interactions rather than direct cytotoxicity. By remodeling the bloodstream microenvironment and enhancing immune defense, SF may represent a promising and safe candidate for the prevention of breast cancer metastasis.

We summarize the cancer-type-specific expression patterns of PHB1/2 and their prognostic value, and provide an in-depth analysis of the mechanisms by which PHBs confer resistance to platinum drugs, paclitaxel, PARP inhibitors, and radiotherapy through stabilization of anti-apoptotic proteins, mitochondrial protection, and maintenance of cancer stem cell properties. Finally, we catalogue the expanding armamentarium of PHB-targeted interventions, including small-molecule ligands, stapled peptides, DNA aptamers, and siRNA delivery platforms, and discuss the challenges and opportunities for clinical translation. By integrating molecular mechanisms with translational perspectives, this review highlights PHBs as unique regulatory nodes at the intersection of metabolism, signaling, and immunity, and advocates for precision strategies that exploit context-specific PHB functions to overcome therapy resistance and improve cancer treatment.

Using this platform, the dynamic variation of PTP1B activity during the invasion process was successfully captured in a transforming growth factor-β1 (TGF-β1)-induced invasion model of MCF-7 human breast cancer cells, and the responses to anticancer drugs cisplatin (CDDP) and paclitaxel (PTX) were further evaluated. This work provides a new analytical strategy for the dynamic analysis of tumor invasion-related enzyme activity and drug sensitivity evaluation at the single-cell level.

P3, N=130, Active, not recruiting, Fidia Farmaceutici s.p.a. | Recruiting --> Active, not recruiting

P2, N=29, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

P2/3, N=396, Not yet recruiting, Shanghai Chest Hospital

P2/3, N=10, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting

Encapsulated paclitaxel (PTX), otherwise restricted by BBB impermeability, is effectively delivered to intracranial tumors and induces reactive oxygen species-driven immunogenic cell death...Synergizing with the pathogen-mimetic characteristics of BEVs, these signals also elicit an approximately 2-fold increase in intratumoral CD8⁺ T-cell infiltration, overcome immune exclusion, and achieve durable tumor control with extended survival in orthotopic GBM models. Accordingly, this virus-bacteria-drug biohybrid strategy enables targeted brain delivery while simultaneously amplifying antitumor immunity, offering a promising and translatable approach for GBM treatment.